期刊
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
卷 180, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.ejps.2022.106322
关键词
Diabetes mellitus; Sodium -glucose cotransporter 2 inhibitors; Epicardial adiposity; Heart failure; Epicardial adipose tissue
Epicardial adipose tissue plays a physiological role in normal heart function, but can become a cardiac risk factor in pathological conditions. Recent studies suggest that SGLT2 inhibitors can modulate epicardial adiposity and reduce the risk of cardiac complications in diabetic patients.
Epicardial adipose tissue is a layer of adipocytes that physiologically surround the myocardium and play some physiologic roles in normal heart function. However, in pathologic conditions, the epicardial adipose tissue can present a potent cardiac risk factor that is capable of impairing heart function through several pathways, increasing the risk of dysrhythmia and creating an inflammatory milieu around the heart tissues. Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are a relatively newly introduced class of antidiabetes drugs which effec-tively normalize blood glucose via overt glycosuria. Some recent reports suggest that these drugs are able to modulate epicardial adiposity and decrease the risk of cardiac complications in diabetic patients who are at higher risk of epicardial adiposity-dependent cardiac disorders. If proven to be true, these antidiabetic drugs can provide dual benefits as both hypoglycemic agents and as epicardial adiposity normalizing agents, thus providing cardiac benefits. In this study, we discuss the physiological and pathophysiological importance of epicardial adiposity and the potential positive effects of SGLT2is in the diabetic milieu.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据